Search
Search
Tardive Dyskinesia
Tardive dyskinesia (TD) is an abnormal involuntary movement disorder that arises as a common adverse effect in patients using antipsychotic medications, occurring in an estimated 20% of this population. This condition inflicts a substantial negative impact on patient quality of life and clinical outcomes and contributes to the significant rate of nonadherence to antipsychotic medication regimens.
Tardive Dyskinesia 360 is a resource center built for mental health practitioners, designed to educate providers on the proper screening, diagnosis, and treatment of TD. Explore expert video commentary, patient cases activities, instructional videos, and stay up to date on the latest information related to TD care.
This initiative is supported by independent educational grants from Neurocrine Biosciences and Teva Pharmaceuticals.
Videos
Abnormal Involuntary Movement Scale (AIMS) Exam
Psych Congress co-chair Rakesh Jain, MD, MPH, explains the importance of the Abnormal Involuntary Movement Scale (AIMS) exam in the diagnosis and monitoring of patients with tardive dyskinesia.
Abnormal Involuntary Movement Scale (AIMS) Exam
From normal (0) to severe (4), see what real tardive dyskinesia movements look like so you can better assess your patients.
Treatment Discussion Points
Drs. Jain and Kumar provide and in-depth analysis of two new VMAT2 inhibitors approved to treat tardive dyskinesia.
Articles
SAN FRANCISCO—Tardive dyskinesia (TD) is strongly linked with older age, medical comorbidity, and hospitalizations, according to a study of US veterans with serious mental illness presented during a…
Is there any rationale for using both deutetrabenazine (Austedo) and valbenazine (Ingrezza) at the same time? Find out from Psych Congress cochair Rakesh Jain, MD, MPH.
Is there benefit in treating a patient with a VMAT2 inhibitor if they have already had severe tardive dyskinesia for several years? Find out here.
Are medications for tardive dyskinesia effective in mild, moderate, or severe cases? Get the answer from Psych Congress cochair Rakesh Jain, MD, MPH.
Once-daily valbenazine was effective and generally well tolerated in adults with tardive dyskinesia who took the drug for up to 48 weeks, according to a study published online in The Journal of…
Posters
To date, there are no data available regarding psychiatrists' practice patterns related to tardive dyskinesia to guide development of CME programs.
Objective: To evaluate the long-term safety/tolerability and efficacy of deutetrabenazine in patients with TD. Week 54 open-label results are reported in this interim analysis
Objective: To assess healthcare utilization and costs between TD and non-TD patients in a sample of patients from the commercially insured and Medicare Supplemental US populations.
Potential pharmacokinetic interactions between valbenazine and concomitant medications were assessed in Phase 1 studies and using standard in vitro methods.
Objective: To assess patients' impression of treatment benefit from deutetrabenazine for the treatment of TD from the pooled ARM-TD and AIM-TD (24 and 36 mg/day doses) data sets, as compared with the…